Navigation Links
Breast Cancer Prevention Using Abortion Drug Considered

Mifepristone, a drug used for termination of early pregnancies, might be helpful to prevent the development of breast tumors. Scientists reported this from the University of California, whose work has been published// in the journal, 'Science'. Mifepristone or RU486 is a licensed drug that blocks the hormone progesterone. In pregnancy, progesterone is the hormone that helps to maintain pregnancy. If it is depleted the developing fetus can get expelled from the body.

The recent research shows that if the progesterone levels are reduced, then tumor cells get adversely affected and stop growing. This discovery may be helpful to tackle breast cancer and also ovarian cancer.

Scientists are now aware of a gene BRCA-1, which helps to suppress tumor formation. Some women have flaws in this gene, in their chromosomes. Such women are seen to be more prone to develop breast tumors and ovarian tumors. It is seen that over 50% of women with this defective gene ultimately end up with cancer by the time they reach the age of seventy.

Recent studies done in mice have shown that, tumors in women with this defective gene are triggered off by progesterone. Mice with defective gene BRCA-1 were given Mifepristone. Cancerous cells did not develop in them even after one year. But quite surprisingly, all the mice to which the drug was not administered, suffered from tumors by the time they were 8 months old.

The lead researcher Eva Lee divulged that, the researchers found out that progesterone promotes the growth of mammary cells, which carries the flawed gene. The drug mifepristone can block progesterone levels and thus decelerate the growth of cancer cells. The researchers are no doubt, very excited about this discovery as it has opened new vistas for women with a high genetic risk of cancer.

More research will be required to develop a more targeted and safer version of progesterone, before it is used as an anti cancer drug. Th is research has faced stiff opposition from groups of people who resist the idea of medical termination of pregnancies, using drugs.
MST
'"/>




Related medicine news :

1. Consensus on "Combination Therapy" for Breast Cancer
2. Breast cancer treatment to be determined by gene test
3. Breast Feeding prevents obesity later on in life
4. Breast milk is essential
5. Breast Cancer Surgery Causes Psychological problems
6. Breast cancer evidence
7. Letrozole Beats Tamoxifen in Breast Cancer Therapy
8. Breast screening among diabetic women
9. Breast feeding can alter hormones
10. Diet, Sunlight connected to Breast Cancer Risk
11. Additional Radiotheraphy for Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... ... April 28, 2016 , ... Trinity ... Tobacco-Free Kids, a leading force in the fight to reduce tobacco use and ... policies that can help reduce tobacco use. The initiative brings together two organizations ...
(Date:4/28/2016)... Illinois (PRWEB) , ... April ... ... the leading provider of enterprise Data Center Infrastructure Management solutions, announces today ... focuses on feature enhancements in the area of capacity management and optimization, ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... Aesthetic Surgery Education and Anzu®, developers of the AnzuMedical™ Knowledge Sharing and ... Surgery Collaborative Residency Network. The platform is scheduled to launch in July 2016 ...
(Date:4/28/2016)... ... April 28, 2016 , ... Accreditation Commission ... Oncology Pharmacy Association (COPA) to develop a comprehensive Specialty Pharmacy Accreditation with Distinction ... an accreditation distinction. ACHC provides a wide range of pharmacy accreditation services that ...
(Date:4/28/2016)... D.C. (PRWEB) , ... April 28, 2016 , ... The ... and Prevention (CDC) has established an ICD-10-CM code for sarcopenia, giving it recognition for ... the medical community effective October 1, 2016. , Sarcopenia is defined as a combination ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 2016 , Net Sales of $1.90 billion ... the prior year period, and an increase of 1.2% on ... EPS for the first quarter were $0.52 reported, a decrease ... an increase of 29.9% over the prior year period ... guidance for 2016 Zimmer Biomet Holdings, Inc. (NYSE ...
(Date:4/28/2016)... , April 28, 2016 TapImmune,Inc. ... of innovative peptide and gene-based immunotherapeutics and vaccines for the ... be presenting at the 3rd Annual Growth Capital Expo ... th , 2016 at Caesars Palace in Las Vegas, Nevada.  ... on Wednesday, May 4 th by Dr. John ...
(Date:4/27/2016)... --   , Total Sales ... Sales  Clinical sales grow 16% year-over-year  , ... OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser ... quarter ended March 31, 2016 and provided an update ... strategy. First Quarter 2016 Revenue Results by ...
Breaking Medicine Technology: